Black checkmark with a sparkle and a curved line underneath on a white background.
Company

ABVC BIOPHARMA, INC.

Ticker
ABVC
Sector
Industry
Report date
November 10, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight ABVC BIOPHARMA's active licensing agreements, asset growth, patent acquisitions, and milestone payments, reflecting ongoing business activities and pipeline advancement.

Recent developments:
  • ABVC BIOPHARMA doubled its assets in Q2 2025, indicating growth in its financial position [N2].
  • The company entered a licensing agreement with OncoX for commercialization of BLEX 404 in April 2024 [N5].
  • ABVC announced a global licensing deal with ForSeeCon Eye for Vitargus in March 2024 [N6].
  • The company signed an agreement to license its know-how to SPI in February 2024 [N7].
  • ABVC reported a milestone payment from AiBtl BioPharma, which became a subsidiary in January 2024 [N8].
  • ABVC BIOPHARMA received a Taiwanese patent for use of Polygala extract for depressive disorder in October 2023 [N7].
  • The company believes its product ABV-1504 can fill a market void after Prozac, as stated in December 2024 [N4].
  • Plus Therapeutics' after-hours biotech rally in January 2026 included ABVC BIOPHARMA advancing, reflecting sector interest [N1].
Overview

ABVC BIOPHARMA, INC. operates as a clinical stage biopharmaceutical company developing a portfolio of drug candidates and a medical device. The company holds exclusive licensing rights for six compounds from BioLite and co-develops a medical device with BioFirst. Its product pipeline includes seven drug candidates and one medical device, targeting therapeutic areas such as major depressive disorder and vitreous replacement following vitrectomy surgery. ABVC BIOPHARMA has entered into multiple licensing agreements with partners including OncoX, ForSeeCon Eye, SPI, and AiBtl BioPharma, the latter becoming a subsidiary. The company has obtained patents in various jurisdictions, including Taiwan and Australia, for its drug candidates. Revenue generation is limited, with some income from contract development and manufacturing organization (CDMO) services and licensing fees. The company’s financial position as of September 30, 2026, shows limited liquidity with a current ratio below 1.0, indicating potential challenges in meeting short-term obligations. ABVC BIOPHARMA faces typical risks of a clinical stage biopharmaceutical company, including regulatory approval uncertainties, product safety concerns, capital raising needs, and operational risks exacerbated by the COVID-19 pandemic.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. ABVC BIOPHARMA, INC. is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutic drug candidates and medical devices. The company has multiple licensing agreements and patents related to its drug candidates and medical devices. It reported revenues of $795,950 for the period ending September 30, 2025, and net income of $1,149,300 for the period ending September 30, 2026. As of September 30, 2026, the company had cash and cash equivalents of $11,294 and short-term investments of $55,160, with a current ratio of 0.2 and cash ratio of 0.01. The company faces risks related to regulatory approvals, product liability, capital access, and the ongoing impact of the COVID-19 pandemic.

Scenarios for ABVC

Bull case model:

ABVC BIOPHARMA has established multiple licensing agreements with partners for commercialization of its drug candidates and medical devices, indicating progress in business development. The company has secured patents in key markets such as Taiwan and Australia, strengthening its intellectual property position. Recent news highlights asset growth and milestone payments, reflecting operational advancements. The company’s diversified pipeline of seven drug candidates and one medical device addresses therapeutic areas with unmet needs, potentially supporting future revenue generation. Its CDMO services provide some revenue support, and the company has demonstrated ability to raise capital through shareholder financing.

Bear case model:

ABVC BIOPHARMA faces significant risks typical of clinical stage biopharmaceutical companies, including lack of regulatory approvals for its drug candidates and medical devices. The company has limited liquidity, with a current ratio of 0.2 and cash ratio of 0.01 as of September 30, 2026, indicating potential challenges in meeting short-term liabilities. Its revenues remain unsubstantial and dependent on licensing fees and CDMO services. The company is exposed to product liability risks due to known side effects and serious adverse events associated with its products, and currently lacks general liability insurance. The ongoing COVID-19 pandemic poses operational risks including clinical trial disruptions and supply chain challenges. Failure to raise additional capital could materially impair its ability to continue operations and develop its pipeline.

Moat:

ABVC BIOPHARMA's moat is primarily based on its exclusive licensing rights to a portfolio of drug candidates and a medical device, supported by patents granted in multiple jurisdictions. The company's licensing agreements with strategic partners provide avenues for commercialization and potential revenue streams. However, as a clinical stage biopharmaceutical company with limited operating history and revenues, its competitive advantage depends heavily on successful clinical development, regulatory approvals, and effective commercialization of its products. The specialized nature of its drug candidates and proprietary know-how contribute to barriers for competitors, but the company remains exposed to typical industry risks including regulatory hurdles and capital constraints.

Risks overview
Risks summary
The most significant risks for ABVC BIOPHARMA include regulatory approval uncertainties, limited liquidity and capital access, product liability exposure, and operational disruptions related to the COVID-19 pandemic.
Risks details:

• Regulatory Approval Risks: The company has no history of obtaining regulatory approval for new drug candidates and faces uncertainties regarding FDA acceptance of clinical trial data, especially from trials conducted outside the United States. Delays or failures in regulatory approvals could materially affect the business.
• Capital and Liquidity Risks: ABVC BIOPHARMA has limited capital resources and a low current ratio of 0.2 as of September 30, 2026. The company depends on raising additional capital to fund research, development, and operations. Failure to secure sufficient financing could force reduction or discontinuation of operations.
• Product Liability Risks: The company’s drug candidates have known side effects and serious adverse events. ABVC BIOPHARMA faces inherent risks of product liability claims and currently lacks general liability insurance, which could result in substantial liabilities and limit commercialization.
• Operational Risks from COVID-19: The ongoing COVID-19 pandemic impacts clinical trial recruitment, supply chains, capital access, and management focus, creating uncertainties in executing the company’s growth strategy and business plans.

FINAL FORECAST FOR ABVC

Final take one line
ABVC BIOPHARMA is a clinical stage biopharmaceutical company with a diversified pipeline and active licensing agreements, facing typical industry risks including regulatory, capital, and operational challenges.
Final take 12 to 24 month view

Business trends: Continued licensing agreements and patent acquisitions support pipeline development and potential commercialization pathways.
Execution milestones: Progress in clinical trials, milestone payments, and asset growth demonstrate operational advancement.
Key risks: Regulatory approval uncertainties, limited liquidity and capital access, product liability exposure, and COVID-19 related operational disruptions.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • ABVC BIOPHARMA, INC. is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutic drug candidates and medical devices.
  • The company has acquired sole licensing rights to develop and commercialize six compounds from BioLite and co-develop a medical device with BioFirst, collectively called the ABVC Pipeline Products.
  • ABVC BIOPHARMA researches and develops seven drug products and one medical device: ABV-1501, ABV-1504, ABV-1505, ABV-1519, ABV-1702, ABV-1601, ABV-1703, and a medical device.
  • The company has entered multiple licensing agreements for commercialization of its products, including deals with OncoX for BLEX 404, ForSeeCon Eye for Vitargus, SPI for licensing its know-how, and AiBtl BioPharma, which became a subsidiary.
  • ABVC BIOPHARMA has received patents, including a Taiwanese patent for use of Polygala extract for depressive disorder and an Australian patent for PDC-1421 for treatment of major depressive disorder (MDD).
  • The company reported doubling its assets in Q2 2025.
  • ABVC BIOPHARMA's products have known side effects and serious adverse events, including those related to Maitake mushroom extract and Radix Polygala (Polygala tenuifolia Willd).
  • The company faces inherent risks of product liability claims and currently maintains insurance coverage for clinical trials but not general liability insurance.
  • ABVC BIOPHARMA has limited operating history, generates unsubstantial revenues, and is dependent on raising capital to fund research and development and operations.
  • The company reported revenues of $795,950 for the period ending September 30, 2025, and net income of $1,149,300 for the period ending September 30, 2026.
  • As of September 30, 2026, ABVC BIOPHARMA had cash and cash equivalents of $11,294, short-term investments of $55,160, current assets of $1,404,384, and current liabilities of $7,192,554, resulting in a current ratio of 0.2 and a cash ratio of 0.01.
  • The company is subject to risks related to the COVID-19 pandemic impacting clinical trials, supply chain, capital access, and management focus.
  • ABVC BIOPHARMA has not obtained regulatory approval for any new drug candidate and faces risks related to FDA acceptance of clinical trial data, especially from trials conducted outside the United States.
  • The company must complete extensive preclinical and clinical trials to demonstrate safety and efficacy before marketing approval can be obtained.
  • The company’s growth depends on its ability to develop, acquire, or license new drugs and successfully commercialize them.
  • The company’s CDMO services generate limited revenue that partially supports operations, with additional funding historically from shareholder financing or loans.
  • The company’s clinical trials and product development are subject to regulatory, operational, and financial risks that could materially affect its business and prospects.
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
  • S1
  • S2
Sources - SEC Filings
  • S1 | 2026-03-03 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-01-15 | www.nasdaq.com | Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance | https://www.nasdaq.com/articles/plus-therapeutics-spurs-after-hours-biotech-rally-connect-biopharma-and-elutia-also
  • N2 | 2025-08-14 | www.nasdaq.com | Abvc BioPharma Doubles Assets in Q2 | https://www.nasdaq.com/articles/abvc-biopharma-doubles-assets-q2
  • N3 | 2025-07-08 | www.nasdaq.com | Tuesday Sector Leaders: Biotechnology, Oil & Gas Exploration & Production Stocks | https://www.nasdaq.com/articles/tuesday-sector-leaders-biotechnology-oil-gas-exploration-production-stocks
  • N4 | 2024-12-19 | www.nasdaq.com | ABVC BioPharma believes ABV-1504 can fill void in market after Prozac | https://www.nasdaq.com/articles/abvc-biopharma-believes-abv-1504-can-fill-void-market-after-prozac
  • N5 | 2024-04-17 | www.nasdaq.com | ABVC BioPharma Enters Licensing Agreement With OncoX For Commercialization Of BLEX 404 | https://www.nasdaq.com/articles/abvc-biopharma-enters-licensing-agreement-with-oncox-for-commercialization-of-blex-404
  • N6 | 2024-03-26 | www.nasdaq.com | ABVC Announces Global Licensing Deal With ForSeeCon Eye For Vitargus | https://www.nasdaq.com/articles/abvc-announces-global-licensing-deal-with-forseecon-eye-for-vitargus
  • N7 | 2024-02-15 | www.nasdaq.com | ABVC Signes Agreement To License Its 'Know-How' To SPI | https://www.nasdaq.com/articles/abvc-signes-agreement-to-license-its-know-how-to-spi
  • N8 | 2024-01-03 | www.nasdaq.com | ABVC BioPharma Reports Milestone Payment From From AiBtl BioPharma; AiBtl Becomes Subsidiary | https://www.nasdaq.com/articles/abvc-biopharma-reports-milestone-payment-from-from-aibtl-biopharma-aibtl-becomes
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine